Diabetic Nephropathy Market to reach $5,515.8 million by 2035

Diabetic nephropathy market was valued at $3,177.9 million in 2025 and is projected to reach $5,515.8 million by 2035, growing at a CAGR of 5.2% during the forecast period 2026 to 2035, according to a new report by the Orion Market Research. The diabetic nephropathy market is driven by multiple factors, including growing awareness of early kidney screening, improved diagnostic technologies, increasing availability of disease-modifying therapies, and rising demand for dialysis and long-term renal care. However, the escalating global diabetes burden remains the most significant growth driver. The rapid increase in both diagnosed and undiagnosed diabetes cases is directly expanding the at-risk population for kidney complications which is leading to higher incidence of diabetic nephropathy and sustained demand for prevention, treatment, and renal care solutions globally.

Browse the full report description of “Diabetic Nephropathy Market Size, Share & Trends Analysis Report by Indication (Diabetes Type-1, and Diabetes Type-2), By Diagnosis (Urine Test, Imaging Test, Blood Test, Renal Function Test, and Renal Biopsy), and By Treatment (Medications, Kidney Dialysis, Kidney Transplant), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/diabetic-nephropathy-market

Rising Global Diabetes Burden Driving Diabetic Nephropathy Demand

According to the International Diabetes Federation (IDF), the global adult diabetes population is projected to reach 853 million by 2050, meaning one in eight adults could be living with diabetes. Alarmingly, around 43% of diabetic adults (about 252 million people) remain undiagnosed, increasing the risk of late-stage complications. According to a research study published by the U.S. National Library of Medicine (NLM), the rising prevalence of diabetes is directly associated with a steady increase in the burden of diabetic nephropathy, one of the most common long-term complications of the disease.

As per the research published at US National Library on Medicine a significant proportion of diabetic patients eventually develop kidney damage. Studies indicate that around 30% of Type 1 diabetes patients and nearly 40% of Type 2 diabetes patients progress to diabetic nephropathy. In many Type 2 diabetes cases, kidney damage may already be present at diagnosis due to delayed disease detection. Over time, diabetes leads to progressive loss of kidney function, resulting in protein leakage, rising blood pressure, and ultimately chronic kidney disease.

This surge in number of patients with declining renal function is driving sustained demand for early diagnostic testing, disease-modifying drugs, dialysis services, and long-term renal care solutions. As healthcare systems focus on slowing disease progression and managing advanced kidney complications, the expanding diabetes population continues to act as a strong and long-term growth driver for the global diabetic nephropathy market.

Recent Key Developments in the Diabetic Nephropathy Market 

• In April 2025, Palatin Technologies presented positive data from its Phase 2b BREAKOUT clinical study evaluating a melanocortin agonist therapy for Type 2 diabetic nephropathy at the National Kidney Foundation Spring Meeting in Boston. The study demonstrated clinically meaningful improvements in key kidney function markers, including reduced proteinuria and stabilized eGFR in treated patients, highlighting the therapy’s potential to slow disease progression in diabetic kidney disease.

• In January 2025, the S. Food and Drug Administration (FDA) approved Novo Nordisk’s Ozempic (semaglutide) to reduce the risk of kidney failure and disease progression in adults with type 2 diabetes and chronic kidney disease.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Indication
• Diagnosis
• Treatment

• Competitive Landscape – AstraZeneca PLC, Bayer AG, Novartis AG, Pfizer Inc. and Sanofi S.A.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Diabetic Nephropathy Market Report Segment

By Indication

• Diabetes Type-1
• Diabetes Type-2

By Diagnosis

• Urine Test
• Imaging Test
• Blood Test
• Renal Function Test
• Renal Biopsy

By Treatment

• Medications
• Kidney Dialysis
• Kidney Transplant

Global Diabetic Nephropathy Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/diabetic-nephropathy-market